Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
Leconet W, Larbouret C, Chardès T, Thomas G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M, Bernex F, Penault-Llorca F, Pasquet JM, Pèlegrin A, Robert B.
Leconet W, et al. Among authors: larbouret c.
Oncogene. 2014 Nov 20;33(47):5405-14. doi: 10.1038/onc.2013.487. Epub 2013 Nov 18.
Oncogene. 2014.
PMID: 24240689
Free PMC article.